Cardiology in California

Starboard Medical is a US-based, woman co-owned medical device manufacturer specializing in temperature management products and thermistor sensor technologies. The company produces a range of temperature probes and sensors including esophageal stethoscopes, general-purpose temperature probes, skin temperature sensors, and tympanic temperature sensors for clinical monitoring applications. Beyond branded products, Starboard offers comprehensive OEM and contract manufacturing capabilities including insert molding, injection molding, dip molding, tubing extrusion, and full packaging services. The company serves medical device OEMs and healthcare facilities requiring specialized temperature sensing solutions and manufacturing partnerships.

RefleXion Medical develops biology-guided radiotherapy (BGRT) systems for cancer treatment. The company's flagship product, the RefleXion X1 machine with SCINTIX autonomous radiotherapy, combines PET (positron-emission tomography) imaging with linear accelerator (LINAC) radiation therapy to enable real-time tumor tracking and treatment delivery. SCINTIX detects biological signals emitted by cancer cells after radiopharmaceutical injection and uses this information to autonomously guide radiation beams to tumors in motion, potentially reducing dose to surrounding healthy tissue. The system is FDA-cleared for treatment of lung and bone tumors, including primary and metastatic disease at any stage. In addition to SCINTIX therapy, the RefleXion X1 platform delivers conventional radiotherapy modalities including SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), and IMRT (intensity-modulated radiation therapy) for solid tumors throughout the body. The platform is designed to fit standard radiotherapy vaults with minimal shielding modifications and is compatible with third-party immobilization devices and existing contouring tools. Founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri, RefleXion has secured over $400 million in venture financing and employs more than 250 people. Leadership includes Todd Powell (President and CEO, formerly of Elekta) and Martyn Webster (CFO). SCINTIX therapy has achieved Medicare reimbursement through multiple Medicare Administrative Contractors (MACs), supporting adoption in freestanding cancer centers and hospital outpatient departments. The company targets oncology departments, cancer centers, and radiation therapy facilities.

West Coast Surgical is a contract manufacturer and design-to-production partner specializing in surgical devices and instrumentation. With over 20 years of experience, the company focuses on cardiovascular, neuro, and spine instruments, offering end-to-end services from concept development through finished device manufacturing. Core capabilities include device design and development, contract manufacturing, prototyping, and design for manufacturing (DFM). The company operates FDA-registered facilities in Half Moon Bay, California and Houston, Texas, equipped with advanced machining capabilities including CNC milling (5-axis), Swiss lathes, wire EDM, heat treating, and inspection/quality control systems. West Coast Surgical serves both established medical device companies and emerging ventures, with expertise in regulatory compliance and quality system implementation.

Uptake Medical Technology Inc. is a San Jose, California-based medical device manufacturer specializing in bronchoscopic thermal vapor ablation (BTVA) systems for pulmonary disease treatment. The company's primary product, InterVapor® (also known as BTVA®), is a non-surgical, non-implant therapeutic system designed to treat severe emphysema and select lung malignancies through vapor ablation technology. The procedure involves delivery of heated, purified water (steam) via a thin bronchoscope inserted through the patient's airway to diseased lung tissue, resulting in tissue ablation and removal via natural healing processes. Treatments typically require less than 15 minutes and can be performed under light sedation in an outpatient bronchoscopy setting. The vapor ablation mechanism targets severely diseased lung regions to improve pulmonary function and breathing capacity in patients with severe emphysema, potentially enhancing quality of life. The company markets its technology as a minimally invasive alternative to surgical lung volume reduction. Note: InterVapor is not currently approved for use in the United States, limiting domestic commercial availability. The company's regulatory and clinical development strategy targets international markets and regulatory approval pathways.

Alpha-Omega Services, Inc. (AOS) is a specialized contract manufacturer and supplier of radiation therapy products and radioactive material handling solutions, operating since 1973. The company serves radiation therapy OEMs, industrial entities, and research organizations with sealed contract manufacturing of Iridium-192 (Ir-192) HDR brachytherapy sources for medical device manufacturers, NRC-certified Type B transport casks for secure shipment of radioactive materials (including the AOS-100 series featuring trunnions and dual-end lids), and expert consulting on complex radioactive material projects and regulatory compliance. AOS holds multiple industry licenses and NRC certifications, ensuring compliance with nuclear regulatory standards. The company emphasizes over 50 years of manufacturing excellence, regulatory compliance, quality control, and competitive pricing for OEMs, distributors, and healthcare providers. AOS provides sealed source manufacturing, radioactive material (RAM) handling and packaging, and specialized consulting for medical device manufacturing and regulatory approval processes.

HillTek LLC is the United States distributor of HiToP® (High-Tone Therapy), an advanced, patented cellular optimization technology developed and manufactured by gbo Medizintechnik AG in Germany since 1969. HiToP® is a Class II medical device (FDA-cleared) and CE-marked under European medical device regulations, backed by over 30 published peer-reviewed scientific papers. The technology uses patented high-frequency modulated electrical energy to optimize cellular voltage, promote mitochondrial energy production, and enhance cellular diffusion, supporting whole-body and localized therapeutic applications. HiToP® is non-invasive, hands-free, and clinically indicated for functional medicine (pain reduction and chronic illness management), wellness and longevity (cellular rebalancing and restoration), and sports medicine (recovery acceleration and performance optimization). The product line includes three models: HiToP® 1touch (single-channel, portable, up to 5000 mW), HiToP® 2touch (dual-channel, scaled efficiency), and HiToP® 4touch (four independent channels for advanced clinical environments). All devices deliver comparable power to high-power laser therapy while remaining gentle and well-tolerated, typically producing only subtle tingling sensations. HiToP® holds 3 international patents and is designed for healthcare, wellness, and performance professionals in functional medicine clinics, integrative medicine practices, athletic teams, and boutique wellness facilities. Manufacturing and design are entirely German-engineered.

CMR Naviscan Corporation manufactures and markets molecular breast imaging (MBI) systems for breast cancer detection and diagnosis. The company's primary product is the lumaGEM system, a gamma imaging platform designed for screening and diagnostic applications in breast imaging. The lumaGEM system is used as a primary screening option, secondary screening modality for high-risk patients and those with dense breast tissue, and for adjunct evaluation of occult primary breast carcinoma and equivocal conventional imaging findings. The company also offers the Solo II imaging platform and Stereo Navigator navigation system. Clinical data presented on their site demonstrates increased invasive cancer detection rates, reduction of benign biopsies in women with dense breast tissue compared to other modalities, and lower cost per cancer detected when MBI is added to screening mammography. The lumaGEM system is positioned to address the significant clinical challenge of dense breast tissue, where both cancer and fibroglandular tissue appear white on conventional mammography, reducing sensitivity. CMR Naviscan's solutions are used by radiologists and breast cancer centers for both screening and diagnostic purposes, with published evidence supporting efficacy in early cancer detection. The company participates in major industry conferences such as the Society of Breast Imaging symposium.

Applied BioPhotonics Ltd (ABP) is a manufacturer of photobiomodulation therapy (PBT) devices and systems that use light energy to non-invasively stimulate cellular healing and recovery. The company's flagship Mark II system employs LED-based red, infrared, blue, violet, and green wavelengths delivered via flexible, hypoallergenic 3D LightPads to treat tissue-specific conditions. Products are marketed globally under regional brands: LightMD (USA/Europe), AraLight (India/Middle East/Africa), LightDr (Asia/Japan), PetLight (veterinary), and EquineLight (equine). The system features the proprietary LightOS user interface with dozens of tissue-specific treatment protocols, interchangeable pad configurations for different body parts, and precise pulse frequency controls. Clinical applications span pain management, inflammation reduction, musculoskeletal injury recovery, post-operative healing, circulation improvement, fatigue reduction, concussion recovery, and dermatological conditions. ABP serves physicians, hospitals, physical therapists, chiropractors, dermatologists, surgical specialists, dentists, wellness clinics, athletic trainers, and veterinarians. The company holds FDA audit approval, ISO 13485 certification, Taiwan FDA clearance, IEC eye-safety rating, FCC clearance, GMP manufacturing certification, CE marking, and RoHS compliance. Products are non-invasive, non-toxic, non-addictive, and classified as non-pharmaceutical devices. Manufacturing emphasizes medical-grade quality polymers, hypoallergenic materials, and rigorous safety testing.

NEO Science, headquartered in Glendale, California, is a leading distributor and innovator in health optimization technologies, specializing in advanced photobiomodulation (red/infrared light therapy) and whole-body cryotherapy equipment. Founded by Robin Kuehne, a 15+ year industry pioneer who introduced cryotherapy to the US, NEO Science designs and distributes cutting-edge wellness devices for spas, recovery centers, chiropractic clinics, and medical wellness facilities. The company's product portfolio includes the NEO Light Bed (full-body photobiomodulation system with customizable light modes), NEO Pod and NEO Cool (targeted cryotherapy units), and integration with Starpool premium wellness systems. NEO Science emphasizes touchless technology, non-invasive treatment protocols, and proven clinical benefits including muscle recovery, cellular energy production, collagen stimulation, wound healing acceleration, and anti-aging outcomes. B2B-focused, offering white-glove setup, financing, custom branding support, and training to help wellness businesses unlock new revenue streams. Recognized as a 2025 Inc. 5000 fastest-growing company and 2025 CINA Best Customer Service Award winner.

CG MedTech USA, Inc. (Irvine, California) is a specialized manufacturer of orthopedic and spinal implant technologies serving Ambulatory Surgery Centers (ASCs), hospitals, and surgical specialists. The company offers a comprehensive portfolio spanning spinal implants, trauma fixation systems, sports medicine devices, pain management solutions, and biologic products. With a commitment to value-based pricing, CG MedTech provides competitively priced, quality-assured implants that challenge market premiums while maintaining rigorous R&D investment and industry compliance. The company serves manufacturers, distributors, surgeons, hospitals, and patients with a focus on clinical outcomes and procurement efficiency. Global operations include headquarters in South Korea and dedicated U.S. sales and R&D centers, positioning CG MedTech as a reliable partner for cost-effective orthopedic solutions without compromising device quality or performance.

CorTechs Labs is a SaaS-based medical imaging software company specializing in AI-powered quantitative analysis of brain and oncological imaging. The company develops advanced algorithms for automated brain segmentation, volumetric analysis, and lesion quantification across MRI, CT, and PET modalities. Their solutions enable clinicians to detect and monitor neurodegenerative diseases (dementia, Alzheimer's, multiple sclerosis), brain tumors, and prostate cancer with improved diagnostic confidence and efficiency. CorTechs' flagship NeuroQuant® platform has processed over 2 million brain scans across 1,500+ medical institutions in 44 countries, providing radiologists with rapid, objective measurements for disease progression tracking and comparative analysis against normative databases. The company also offers OnQ™ Prostate for prostate MRI analysis and specialized tools for lesion surveillance and post-operative assessment. Solutions integrate with major OEM imaging platforms (GE, Siemens, Philips, Canon) and are supported by Category III CPT codes for reimbursement.

Cooler Heads Care, Inc. manufactures the Amma™ Scalp Cooling System, an FDA-cleared medical device designed to reduce chemotherapy-induced hair loss in cancer patients. The system is intended for adults 21 and older undergoing treatment for solid tumors. Amma consists of four integrated components: a custom-fitted cooling wrap that delivers chilled solution to the scalp, a neoprene compression strap, a compression cap for secure fit, and a portable cooling unit that circulates and maintains optimal temperature. The device operates by cooling the scalp before, during, and after chemotherapy administration, thereby reducing chemotherapy drug penetration to hair follicles and supporting hair preservation and regrowth. Treatment protocol requires cooling initiation 30 minutes before chemotherapy and continuation for 2–3 hours post-infusion. The Amma system is distinguished by its portability, allowing patients mobility throughout infusion centers, and features a custom-fitted wrap requiring no mid-session adjustments. The company provides comprehensive patient and clinical staff support through a dedicated customer care team, training tools, and clinical guidance. Cooler Heads has received backing from established accelerators and research institutions including StartX, Endless Frontier Labs, and the NIH National Cancer Institute, and is recognized by MedTech Innovator and the California Technology & Innovation Program. The product addresses multiple medical and psychosocial contraindications and requires provider prescription and infusion center availability.

DT Research, Inc. is a Silicon Valley-based industrial computing manufacturer founded in 1995, specializing in purpose-built rugged computing systems for healthcare, government, and enterprise environments. The company designs and manufactures medical tablets, medical cart computers, medical all-in-one systems, rugged convertible laptops, and digital signage solutions. All medical products carry ANSI/AAMI ES60601-1 certification and feature antimicrobial coatings. DT Research emphasizes deployment-ready, customized solutions with integrated software and hardware, rigorous testing, and assembled-to-order manufacturing. The company provides device management software, fleet management tools (WebDT Battery Fleet Manager), and long-term support services. With engineering teams and production facilities across California and Asia, DT Research serves hospitals, military, government agencies, and logistics/manufacturing sectors worldwide.

STARmed America, Inc. is the U.S. subsidiary of South Korean medical device manufacturer STARmed Co., Ltd., established in October 2023. Based in Los Angeles, the company specializes in FDA-cleared radiofrequency ablation (RFA) systems and electrodes for minimally invasive treatment of soft tissue conditions. STARmed offers four RFA generator systems and over ten types of electrodes, including the pioneering thyroid-dedicated RF electrode first developed in 2004. Products are designed for percutaneous and endoluminal ablation applications across thyroid, liver, kidney, lung, bone, biliary, pancreatic, and uterine fibroid conditions. The company currently supports over 120 medical facilities across 36 U.S. states and has trained more than 300 physicians. STARmed provides comprehensive program support including hands-on training, clinical case assistance, reimbursement guidance, and marketing support, with 96% physician satisfaction rates.

ImpediMed is a medical technology company specializing in bioimpedance spectroscopy (BIS) devices for noninvasive clinical assessment and monitoring of fluid status and tissue composition. The company's flagship SOZO® Digital Health Platform is FDA-cleared and enables real-time measurement of body composition, fluid volumes, and tissue changes across multiple clinical applications. Primary use cases include early detection and monitoring of secondary lymphedema in cancer survivors, heart failure fluid management, medical weight management assessment, and wellness/longevity monitoring. The SOZO platform utilizes advanced BIS technology measuring 256 frequencies to separate intra- and extracellular fluid and deliver actionable insights at point of care. The company operates a cloud-connected SaaS model supporting personalized care monitoring across the patient treatment continuum, with global distribution in US, Europe, Australia, and other markets.

Color Diagnostics is an oncology-focused clinical care platform that delivers comprehensive cancer management services across prevention, early detection, diagnosis, active treatment, and survivorship. The company operates a licensed medical group across all 50 states staffed by board-certified oncologists who provide direct clinical care rather than navigation-only services. Color's Virtual Cancer Clinic model addresses fragmented traditional cancer care by offering 24/7 access to oncologist-led teams, at-home cancer screening and testing, peer-to-peer collaboration with treating providers, and active treatment care management with symptom monitoring. The platform targets employers, health plans, consultants, unions, and public sector organizations seeking to improve cancer outcomes while controlling costs. Key clinical capabilities include early risk identification, higher screening completion rates, fast follow-up on abnormal results, and long-term survivorship management to support return to work. Color reports clinical outcomes including 53% faster diagnosis, 62% increase in screening adherence, closure of >60% of costly care gaps, $18,235 average savings per patient, and 2.7:1 ROI in Year 1. The company serves major employers and organizations across multiple industries and demonstrates commitment to accessible, evidence-based oncology care delivery.

Free Flow Medical is a pulmonary medicine company developing and providing targeted treatments for chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's primary product is the FreeFlow® Coil System, a bronchoscopic lung volume reduction (BLVR) treatment device indicated for patients with severe emphysema. The Coil System is designed to improve lung function, exercise capacity, and quality of life in affected patients. The technology operates independently of collateral ventilation presence, offering flexibility in patient selection. Free Flow Medical positions itself as a lung specialist focused on advancing pulmonary medicine through innovative interventional treatments. The company is registered as Free Flow Medical GmbH and operates from Düsseldorf, Germany. The website indicates the FreeFlow® Coil System is not currently approved for sale in the United States, suggesting the company is primarily focused on European and international markets. The device represents a minimally invasive endoscopic intervention approach to lung volume reduction, targeting a significant patient population with limited treatment options. Free Flow Medical maintains a professional healthcare provider portal and engages with clinical audiences through educational content and product information.

Pulmonx Corporation is a global medical technology company headquartered in Redwood City, California, with operations in Neuchâtel, Switzerland, founded in 1995. The company specializes in minimally invasive bronchoscopic interventions for severe emphysema and chronic obstructive pulmonary disease (COPD). Pulmonx pioneered bronchoscopic lung volume reduction (BLVR) technology and has established itself as a leader in interventional pulmonology solutions for patients unsuitable for or unresponsive to surgical intervention. The company's flagship product portfolio includes the Zephyr® Endobronchial Valve, a clinically validated device that reduces lung hyperinflation by occluding diseased airways, demonstrating significant improvements in lung function (FEV1), exercise capacity, and quality of life across multiple randomized controlled trials. The Chartis® Pulmonary Assessment System provides collateral ventilation assessment to optimize patient selection and treatment planning. The LungTraX Platform delivers cloud-based quantitative CT analysis for personalized treatment planning. Pulmonx's devices are FDA-approved and supported by extensive clinical evidence across four major randomized controlled trials, with over 100 published clinical summaries. The company maintains a global network of treating physicians and assessment centers, with rigorous credentialing criteria including specialized training, hands-on competency, and outcomes monitoring.

Totex Manufacturing Inc. is a US-based designer and manufacturer of custom battery packs and charging systems serving medical, industrial, aerospace, and consumer markets since 1985 (35+ years of experience). The company provides comprehensive solutions from initial design through manufacturing, testing, and global logistics. In the medical sector, Totex supplies rechargeable batteries and chargers for portable diagnostic devices (ultrasound machines, blood pressure monitors, insulin pumps, portable monitors), portable medical equipment, and ICU/emergency devices requiring reliable power in demanding environments. The company manufactures to rigorous medical standards and maintains FDA registration. Core manufacturing capabilities include circuit design and PCB layout, fuel gauge and MCU firmware programming, in-house SMT assembly (7 fully automatic lines), plastic injection molding (27 machines), ultrasonic and spot welding, and automated cell sorting. Quality systems include ISO 9001, ISO 13485, and ISO 14001 certifications, with in-house UL2054 testing, Six Sigma training (1 master black belt, 2 black belts, 30+ green belts), and DPPMs typically <500 per year. Environmental testing capabilities in-house include temperature cycling, thermal shock, humidity, IP68 dust/water intrusion, vibration, drop, shock, and nail penetration testing. The company operates two manufacturing facilities (Torrance, California: 55,000 sq. ft.; Huizhou, China: 120,000 sq. ft.) with vertical integration enabling cost-effective and consistent production. Expertise spans all major cell chemistries: Li-Ion, LiFePO4, NiMH, Li-SOCl2. Logistics support includes ~98% on-time delivery, Kanban/VMI/consignment programs, and specialized handling of lithium-ion battery shipping regulations. Designs include autoclave and intrinsically safe ratings for medical applications.

Artera is an AI-powered precision oncology company developing multimodal artificial intelligence (MMAI) platforms that analyze digital pathology and clinical data to provide personalized cancer treatment recommendations. The company operates a CLIA-certified laboratory in Jacksonville, Florida, delivering laboratory-developed tests (LDTs) for cancer risk stratification and treatment guidance. ArteraAI Prostate Test, the company's flagship offering, received FDA De Novo Authorization as Software as a Medical Device (SaMD), making it the first and only AI test recommended in NCCN Clinical Practice Guidelines for Prostate Cancer. The test provides risk stratification for early-stage prostate cancer patients and predicts which NCCN Intermediate-risk patients will benefit from short-term androgen-deprivation therapy with radiation. The Prostate Test analyzes existing H&E histopathology slides without additional staining, delivers results within 1–2 days, demonstrates consistent performance across diverse populations, and is covered by Medicare and many commercial insurers. Artera also offers the ArteraAI Breast Cancer Test, providing 5- and 10-year distant metastasis risk assessment for early-stage breast cancer and identifies node-negative patients 50+ years old who may benefit from chemotherapy. The platform has been validated across dozens of large randomized phase III clinical trials. Artera maintains headquarters in Los Altos, California, with clinical laboratory operations in Jacksonville, Florida.

NeuraSignal is a medical technology company specializing in advanced transcranial Doppler (TCD) ultrasound systems enhanced through robotics, artificial intelligence, and cloud computing. Founded in 2013 and based in Los Angeles, the company develops FDA-cleared intelligent ultrasound platforms designed to automate and improve cerebral hemodynamics assessment for stroke detection, patent foramen ovale (PFO) screening, and vasospasm monitoring. The NG2 Intelligent Ultrasound system uses robotic control and machine learning algorithms to automatically locate the temporal window and lock onto cerebral blood flow signals with accuracy comparable to expert sonographers, while eliminating operator variability. The NeuraSignal Platform provides cloud connectivity enabling remote access, real-time data collaboration, and advanced analytics for clinical decision-making. Their portable Lucid™ TCD systems support both clinical deployment in hospital settings and international research initiatives. The technology is particularly valued in comprehensive stroke centers and neuroscience programs for its noninvasive nature, painless administration, and superior detection rates—clinical data demonstrates 3× shunt detection rates and 2.7× detection of intervenable shunts compared to standard transthoracic echocardiography (TTE).

Cala Health is a bioelectronic medicine company specializing in wearable neuromodulation therapies for chronic diseases. Founded in 2014 as a Stanford University spinout, Cala develops non-invasive peripheral nerve stimulation devices using transcutaneous afferent patterned stimulation (TAPS). The company's flagship product, the Cala kIQ, is an FDA-cleared wrist-worn device for reducing action hand tremor in essential tremor and Parkinson's disease patients. The Cala kIQ delivers on-demand TAPS therapy with clinically proven efficacy—patients report tremor reduction within 40 minutes, with relief lasting over 90 minutes post-session. The company supports a comprehensive patient lifecycle ecosystem including prescription fulfillment, insurance reimbursement assistance, connected care services via MyCala.com patient portal, telemedicine consultation, and medication management support. Medicare and VA coverage are available for qualifying beneficiaries. Cala Health is expanding its therapeutic focus to neurology, cardiology, and psychiatry applications.

IEI Integration Corp. is a Taiwan-based edge computing and embedded systems manufacturer specializing in AI-ready industrial computers, fanless systems, and medical-grade solutions. The company designs and manufactures box PCs, panel PCs, embedded systems, network appliances, and specialized medical imaging capture systems. IEI offers an ODM (Original Design Manufacturing) service for custom embedded computing solutions across multiple verticals including healthcare, smart factories, autonomous mobile robots, and networking infrastructure. The company holds TFDA (Taiwan FDA) and ISO 13485 certifications for medical device manufacturing, demonstrating compliance with international medical device quality standards. Product lines include the HTB series (medical AI box PCs with 24-core processors and touchscreen displays), TANK AIoT developer kits, PUZZLE network appliances, and the EndoCap-3588 endoscopic image capture and recording system designed for medical visualization and diagnostics. IEI supports Intel and AMD processors, GPU acceleration (Nvidia Quadro RTX), real-time computing with Intel TCC/TSN, and integrated AI inference via OpenVINO and Intel Movidius Myriad X accelerators. The company manufactures in Taiwan with new facility expansion in Yangmei and maintains a US presence through IEI Technology USA Corp. Services include technical support, warranty coverage, software services, and end-of-life product management. IEI serves OEMs, medical device manufacturers, industrial automation integrators, and healthcare facilities requiring edge AI computing, real-time data processing, and ruggedized embedded platforms.

IceCure Medical manufactures the ProSense® Cryoablation System, a liquid-nitrogen-powered minimally invasive tumor ablation platform. The system uses ultra-low temperatures (below −170°C) to freeze and destroy benign and malignant tumors across multiple clinical applications. Primary indications include early-stage breast cancer in low-risk patients aged 70+ with tumors ≤1.5 cm (FDA-cleared for local treatment with endocrine therapy), kidney cancer, lung cancer, fibroadenomas, and palliative care applications. The ProSense system delivers rapid and stable freezing via a single cryoprobe inserted under ultrasound guidance, typically requiring 30–45 minute outpatient procedures under local anesthesia with minimal recovery time (median 1 day return to normal activity). Clinical evidence from the ICE3 trial demonstrates 3.1% local recurrence rate at 5 years in breast cancer patients treated with cryoablation plus endocrine therapy, with 99.1% patient and 97% physician satisfaction regarding cosmetic outcomes. The technology preserves tissue architecture, avoids general anesthesia and extended hospital stays, and maintains breast shape with minimal scarring. IceCure holds regulatory approvals globally, including FDA 510(k) clearance for breast cancer. The company operates a worldwide distributor network and provides comprehensive support for hospital and office-based practice integration.

IntraOp Medical Corporation is a California-based manufacturer of electron therapy linear accelerators for cancer treatment. The company specializes in intraoperative radiotherapy (IORT) and non-invasive skin cancer treatment using compact, mobile electron beam devices. The Mobetron, IntraOp's flagship product introduced in 1997, is a self-shielded linear accelerator designed for deployment in operating rooms and outpatient settings. The Mobetron delivers precise electron beam therapy with applications in pancreatic cancer (PDAC), intraoperative radiotherapy, and non-melanoma skin cancer treatment. IntraOp is the first to offer ultra-high dose rate (UHDR) electron therapy approved for FLASH radiotherapy clinical trials, enabling preclinical investigation of FLASH on an established clinical platform. The company reports over 40 Mobetron units installed in leading cancer centers globally. IntraOp employs physicists, engineers, and designers in Silicon Valley to develop and support its radiation therapy systems. The Mobetron platform offers advantages including portability, dynamic pulse modulation, larger clinical volumes, excellent cosmesis for skin cancer cases, and reduced patient recovery times compared to surgical alternatives. Regulatory approvals for FLASH trials and clinical deployment in leading oncology centers establish the company's credibility in the radiation oncology market.

New Deantronics is a medical device developer and manufacturer founded in San Francisco in 1985, with engineering and manufacturing operations in Taiwan and a state-of-the-art 200,000 sq. ft. facility in Spanish Springs, Nevada. The company specializes in designing, developing, and manufacturing innovative surgical and medical devices for use in general surgery, neurosurgery, cardiology, orthopedics, and aesthetic medicine. New Deantronics is particularly known for miniaturized medical devices, including nano cameras used in minimally invasive surgical procedures. The company offers comprehensive services including design, development, manufacturing, packaging, sterilization, regulatory compliance, and post-market support. The company emphasizes quality, precision, and innovation, with a strong focus on FDA and ISO 13485 regulatory compliance. New Deantronics also operates medical device incubation centers to support startup innovation in the medical device sector.

Vesalio, Inc is a medical device company specializing in mechanical thrombectomy systems for acute arterial occlusions across neurovascular, coronary, and peripheral vascular territories. The company manufactures a comprehensive platform of patented thrombectomy devices leveraging proprietary Drop Zone™ technology designed to maximize clot retention and first-pass recanalization success. Primary product lines include: NeVa (neurovascular stroke thrombectomy), NeVa NET (next-generation neurovascular system with integrated micro-filter), NeVa VS (post-aneurysmal subarachnoid hemorrhage cerebral vasospasm treatment), enVast (coronary thrombectomy for large thrombus burden), pVasc (peripheral arterial occlusion thrombectomy), and NeVaSC (aspiration catheter). The company holds multiple regulatory clearances including FDA 510(k) clearances for several product lines and CE marks for international markets. Vesalio addresses a significant clinical need across three major disease areas: ischemic stroke (approximately 15 million cases annually, 80% clot-related), acute myocardial infarction (8.5 million cases annually, 30% clot-related), and acute limb ischemia (2.5 million cases annually, 80% clot-related). The platform is supported by robust clinical evidence, with published cases and peer-reviewed data demonstrating high recanalization rates and clinical efficacy across multiple vascular territories.

Qisda Corporation is a global technology conglomerate founded in 1984, headquartered in Taiwan. The company operates across five major business segments: displays, projectors, medical devices, smart solutions, and networking services. In the medical sector, Qisda has developed a diversified medical fleet (醫療艦隊) encompassing six key domains: medical equipment, medical consumables, hemodialysis, medical imaging, health & wellness devices, and medical services. The company owns two large integrated hospitals and operates as both a medical device manufacturer and healthcare distribution provider. Qisda is recognized as a Thomson Reuters Global Tech 100 leader, an Asia Best Employer, and a Taiwan Top 10 Sustainability Enterprise. In displays, Qisda ranks as the world's second-largest LCD panel manufacturer, serving consumer, commercial, professional, and medical applications. In projectors, the company ranks in the global top three, holding the second-largest market share in DLP projection technology. The medical business serves first-line healthcare users with integrated solutions across hospital infrastructure, clinical diagnostics, renal therapy, imaging systems, consumer health products, and healthcare management services. Smart solutions span six verticals: smart retail, smart healthcare, smart energy, smart manufacturing, smart enterprise, and smart education, emphasizing hardware-software integration and one-stop provisioning. The networking division provides comprehensive broadband services including wired/wireless networks, broadband infrastructure, systems integration, and 5G enterprise private networks. Qisda operates manufacturing facilities and sales offices across 60+ countries with approximately 30,000 employees.

United Imaging Healthcare develops and manufactures advanced medical imaging equipment with a mission to provide Equal Healthcare for All. The company produces a comprehensive multi-modality portfolio including CT, MRI, PET/CT, and digital X-ray systems. Key product lines include the uCT® ATLAS CT scanner (up to 640 slices), uMR® 680 1.5T MRI system with uAiFI AI capabilities, uMI® Panorama digital high-resolution PET/CT, and uDR® 380i Pro digital mobile X-ray systems. The company also manufactures the uDR® Aurora CX system and operates translational imaging, interventional X-ray, and remote scanning capabilities. United Imaging serves hospital systems, diagnostic imaging centers, precision medicine facilities, and rural healthcare providers across the United States. The company has demonstrated FDA clearance for multiple products and maintains active research partnerships with academic medical centers including UCSF and UC Davis, focusing on applications in oncology, infectious disease diagnosis, and precision healthcare. Products emphasize accessibility, clinical intelligence, and high-resolution imaging capabilities. The organization participates actively in major medical imaging conferences including RSNA, AHRA, SNMMI, and ISMRM.

ECA Medical Instruments is a manufacturer of single-use, Surgery-Ready™ procedure kits and surgical instruments. The company specializes in pre-assembled, sterile surgical kits that serve as a single-source solution for hospitals and surgical centers, eliminating the need for on-site sterilization and calibration. ECA is recognized as an international authority on torque-limiting instrumentation, a critical capability in orthopedic and spine surgery where precise torque application prevents over-tightening of fasteners and implants. Product lines include orthopedic procedure kits, spine surgery kits (including cervical fusion kits), cardiovascular procedure kits, and neuromodulation instrumentation. All kits are supplied sterile and calibrated on-site before shipment, ensuring compliance with surgical standards and reducing preparation time in the operating room. The company serves market leaders in surgical hospitals, orthopedic centers, and specialty surgical facilities. ECA's manufacturing process integrates instrument sourcing, kit assembly, sterilization, and quality assurance, positioning the firm as a comprehensive vendor for surgical procedure kit solutions.

Ampa Health is a neurotechnology company developing transcranial magnetic stimulation (TMS) systems for treating depression, anxiety, PTSD, and other neurological and mental health disorders. The flagship Ampa One platform delivers accelerated TMS using Synchronized Neuromodulation Therapy (SNT), enabling significantly shorter treatment protocols—potentially one-day treatment—while maintaining clinical efficacy. Clinical data demonstrates 72% remission rates for depression within three months. The system is designed for clinical accessibility, portability, and scalability, with telemedicine capabilities for remote treatment delivery. Ampa targets healthcare providers and mental health facilities seeking evidence-based, efficient neuromodulation solutions to expand treatment capacity and improve patient access to care.

Neurolutions develops the IpsiHand Upper Extremity Rehabilitation System, an FDA-cleared brain-computer interface (BCI) device for home-based motor recovery therapy in chronic stroke survivors. The non-invasive system comprises an EEG headset that captures motor intention signals from the unimpaired brain hemisphere, a powered wireless handpiece that moves the affected hand, and a tablet interface for guided treatment and progress tracking. Clinical data shows approximately 70% of trial participants improved arm and hand function, with an average 8.1-point improvement on the Fugl-Meyer Assessment within 12 weeks. IpsiHand enables patients to overcome recovery plateaus years or decades post-stroke through autonomous home therapy, with broad insurance coverage including Medicare and VA benefits.

Endonovo Therapeutics is a commercial-stage developer of non-invasive wearable medical devices delivering proprietary Electroceutical® Therapy for inflammatory conditions, cardiovascular diseases, and central nervous system disorders. The company's flagship product, SofPulse®, harnesses bioelectricity to restore electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing. Endonovo's Electroceutical® Therapy is FDA-Cleared for palliative treatment of pain and post-surgical edema, with CE Mark for wound healing promotion and pain/edema treatment. The company holds CMS National Coverage for chronic wound treatment. Current pipeline includes clinical-stage therapies targeting ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI), and multiple sclerosis. The technology platform operates through pulsed electromagnetic field (PEMF) delivery mechanisms designed as wearable, non-invasive systems. Endonovo is publicly traded on the OTCQB market (ticker: ENDV) and demonstrates commitment to evidence-based therapeutic development with regulatory-cleared and clinically-validated products.

Bentec Medical OpCo, LLC is a medical-grade silicone fabrication and contract manufacturing specialist founded in 1994 and currently headquartered in Woodland, California. The company operates in two primary segments: (1) OEM contract manufacturing services providing silicone component fabrication, assembly, sterilization, packaging, design consultation, and regulatory support for medical device partners; and (2) proprietary FDA and CE-approved silicone medical devices distributed under the Bentec Medical brand. The company specializes in advanced silicone fabrication capabilities including micro-molding, multi-lumen extrusions, hybrid calendered sheeting, dip coating, and knife coating. Manufacturing expertise encompasses tight-tolerance components, complex multi-process assemblies, and material compounding. Bentec serves OEM customers and direct end-users across oncology, cardiology, urology, pediatrics, bariatric, general and cosmetic surgery, ENT, and interventional radiology specialties. Quality and regulatory credentials include FDA registration, ISO 13485:2016 certification, and ISO 14644 Class 7 cleanroom certification. The company maintains a track record of 100% monthly supplier scorecards from Fortune 500 OEM customers. Manufacturing capabilities combine proprietary techniques with fully validated processes and stringent environmental controls. Bentec was acquired by Hermitage/Greyrock in 2016, which implemented institutional ownership standards, enhanced engineering and quality management systems, and expanded production capacity and fabrication technology.

Avatar Medical USA Inc develops FDA-cleared and CE-marked 3D medical imaging visualization software that transforms DICOM medical images into interactive 3D patient avatars for clinical consultation, surgical planning, and medical education. The platform is hardware-agnostic and integrates with existing PACS systems without preprocessing requirements. It enables real-time 3D visualization suitable for multiple surgical specialties including neurosurgery, oncology, ENT, oral maxillofacial surgery, cardiovascular and vascular surgery, and urology. The software supports intraoperative guidance, multidisciplinary team collaboration, and patient engagement during pre- and post-operative consultations. Avatar Medical also offers Eonis Vision, a consultation-focused product, and Avatar Medical Academy for medical education. The platform supports extended reality (XR) interaction for immersive visualization. Clinical applications span from patient communication and informed consent to detailed surgical planning and training environments. The company serves major teaching hospitals and medical centers across North America and Europe, including Assistance Publique-Hôpitaux de Paris, Sorbonne University, and University of Miami.